News & Events

Learn about what's new with CMC Biologics

CMC Biologics and MacroGenics Enter into a Process Development and Manufacturing Agreement for Oncology Product Candidate


Seattle, Wash. – May 6, 2014CMC Biologics, a global leader in process development and contract manufacturing, and MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into an agreement to further develop the production process for transfer and clinical manufacturing of one of MacroGenics’ product candidates.

Follow Us
Join us on LinkedIn Follow us on Twitter